Autoantibody profiles as biomarkers of breast cancer

Cancer Biomarkers

Volumn 6, Issue 5-6, 2009, Pages 247-256

  Tabernero, Maria Dolores ^a,b,c   Lv, Lin Li ^d   Anderson, Karen S ^e  

^a IECSCYL ^*  (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c CSIC   (Spain)

^d SOUTHEAST UNIVERSITY   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BRCA1 PROTEIN; BRCA2 PROTEIN; CANCER TESTIS ANTIGEN; COMPLEMENTARY DNA; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIVIN; MESSENGER RNA; MUCIN 1; PROTEIN P53; PROTEIN P62; SPERM ANTIGEN; SURVIVIN;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CELL FRACTIONATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; HOUSEKEEPING GENE; HUMAN; INTRADUCTAL CARCINOMA; LUNG CANCER; MAMMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C MYC; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MICROARRAY; REVIEW; SENSITIVITY AND SPECIFICITY; TESTIS CANCER; UTERUS CARCINOMA;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958170264     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0139     Document Type: Review

References (110)

1. Screening for breast cancer: U. S. Preventive Services Task Force recommendation statement, Ann Intern Med 151 (2009), 716-726, W-236.
2. K. S. Anderson et al., Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer, J Proteome Res 7 (2008), 1490-1499.
3. N. L. Anderson et al., The human plasma proteome: history, character, and diagnostic prospects, Mol Cell Proteomics 1 (2002), 845-867.
4. G. A. Balogh et al., Mutant p53 protein in serum could be used as a molecular marker in human breast cancer, Int J Oncol 28 (2006), 995-1002.
5. S. W. Beenken et al., Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53, Ann Surg 233 (2001), 630-638.
6. D. A. Berry et al., Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med 353 (2005), 1784-1792.
7. K. Bouwman et al., Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity, Proteomics 3 (2003), 2200-2207.
8. L. A. Carey et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Jama 295 (2006), 2492-2502.
9. A. Carlsson et al., Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays, Eur J Cancer 44 (2008), 472-480.
10. G. Casey et al., DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies, Oncogene 13 (1996), 1971-1981.
11. C. A. Casiano et al., Tumor-associated antigen arrays for the serological diagnosis of cancer, Mol Cell Proteomics 5 (2006), 1745-1759.
12. C. Chapman et al., Autoantibodies in breast cancer: their use as an aid to early diagnosis, Ann Oncol 18 (2007), 868-873.
13. C. J. Chapman et al., Autoantibodies in lung cancer: possibilities for early detection and subsequent cure, Thorax 63 (2008), 228-233.
14. M. Chatterjee et al., Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays, Cancer Res 66 (2006), 1181-1190.
15. G. Chen et al., Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma, Cancer Res 67 (2007), 3461-3467.
16. S. M. Chen YT, Y. Obata and L. J. Old, Identification of human tumor antigens by serological expression cloning, in: Principles and practice of the biologic therapy of cancer, R. SA, ed., Lippincott Williams & Wilkins, Philadelphia, 2000, pp. 557-570.
17. A. B. De Leo et al., Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse, Proc Natl Acad Sci U S A 76 (1979), 2420-2424.
18. C. Desmetz et al., Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women, Clin Cancer Res 15 (2009), 4733-4741.
19. M. L. Disis et al., Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer, Breast Cancer Res Treat 62 (2000), 245-252.
20. M. L. Disis et al., High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer, J Clin Oncol 15 (1997), 3363-3367.
21. H. A. Doyle et al., Post-translational protein modifications in antigen recognition and autoimmunity, Trends Immunol 22 (2001), 443-449.
22. H. A. Doyle et al., Posttranslational protein modifications: new flavors in the menu of autoantigens, Curr Opin Rheumatol 14 (2002), 244-249.
23. L. J. Esserman et al., A role for biomarkers in the screening and diagnosis of breast cancer in younger women, Expert Rev Mol Diagn 7 (2007), 533-544.
24. F. Fernandez-Madrid et al., Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer, Cancer Res 64 (2004), 5089-5096.
25. F. Fernandez Madrid, Autoantibodies in breast cancer sera: candidate biomarkers and reporters oftumorigenesis, Cancer Lett 230 (2005), 187-198.
26. S. Forti et al., Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum, Breast Cancer Res Treat 73 (2002), 245-256.
27. A. Fossa et al., Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display, Cancer Immunol Immunother 53 (2004), 431-438.
28. A. Fossa et al., NY-ESO-1 protein expression and humoral immune responses in prostate cancer, Prostate 59 (2004), 440-447.
29. R. J. Gao et al., The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters, Breast Cancer Res Treat 93 (2005), 111-115.
30. A. O. Gure et al., Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3, Cancer Res 58 (1998), 1034-1041.
31. A. O. Gure et al., Serological identification ofembryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer, Proc Natl Acad Sci U S A 97 (2000), 4198-4203.
32. L. Harris et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol 25 (2007), 5287-5312. (Pubitemid 350232263)
33. M. E. Hudson et al., Identification of differentially expressed proteinsinovariancancer usinghigh-density protein microarrays, Proc Natl Acad Sci U S A 104 (2007), 17494-17499.
34. M. Isla Larrain et al., Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1), J Exp Clin Cancer Res 28 (2009), 121.
35. D. Jager et al., Antibodies and vaccines-hope or illusion?, Breast 14 (2005), 631-635.
36. D. Jager et al., Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library, Cancer Res 61 (2001), 2055-2061.
37. D. Jager et al., Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene, Cancer Res 59 (1999), 6197-6204.
38. D. Jager et al., Identification oftumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum, Cancer Immun 2 (2002), 5.
39. E. Jager et al., Humoral immune responses of cancer patients against Cancer-Testis antigen NY-ESO-1: correlation with clinical events, Int J Cancer 84 (1999), 506-510.
40. A. Jemal et al., Cancer statistics, 2009, CA Cancer J Clin 59 (2009), 225-249.
41. T. O. Joos et al., Miniaturised multiplexed immunoassays, Curr Opin Chem Biol 6 (2002), 76-80.
42. Z. Kalnina et al., Evaluation of T7 and lambda phage display systems for survey of autoantibody profilesincancer patients, J Immunol Methods 334 (2008), 37-50.
43. D. Kanojia et al., Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer, Cancer Epidemiol Biomarkers Prev 18 (2009), 630-639.
44. K. L. Kellar et al., Multiplexed microsphere-based flow cytometric assays, Exp Hematol 30 (2002), 1227-1237.
45. M. C. Kelley et al., Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma, J Clin Oncol 19 (2001), 1176-1182.
46. J. A. Koziol et al., Recursive partitioning as an approach to selection of immune markers for tumor diagnosis, Clin Cancer Res 9 (2003), 5120-5126.
47. M. L. Kwan et al., Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors, Breast Cancer Res 11 (2009), R31.
48. F. Le Naour et al., Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer, Clin Cancer Res 7 (2001), 3328-3335.
49. C. D. Lehman et al., The role of MRI in breast cancer screening, J Natl Compr Canc Netw 7 (2009), 1109-1115.
50. P. Lenner et al., Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a populationbased epidemiological study, Br J Cancer 79 (1999), 927-932.
51. A. Lernmark, Autoimmune diseases: are markers ready for prediction? J Clin Invest 108 (2001), 1091-1096.
52. R. Lichtenfels et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses, Biochim Biophys Acta 1646 (2003), 21-31.
53. T. H. Lin HS, A. L. Tarca, A. Ionan, M. Chatterjee, B. Ye, J. Wojciechowski, S. Mohapatra, M. D. Basson, G. H. Yoo, B. Peshek, F. Lonardo, C. J. Pan, A. J. Folbe, S. Draghici, J. Abrams and M. A. Tainsky, Autoantibody approach for serum-based detection of head and neck cancer, CancerEpidemiol Biomarkers Prev 16 (2007), 2396-2405.
54. D. A. Litvak et al., Endogenous immune response to earlyand intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors, J Am Coll Surg 198 (2004), 27-35.
55. G. MacBeath et al., Printing proteins as microarrays for high-throughput function determination, Science 289 (2000), 1760-1763.
56. R. D. Marchese et al., Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum, Clin Vaccine Immunol 16 (2009), 387-396.
57. S. Metcalfe et al., P53 autoantibodies in 1006 patients followed up for breast cancer, Breast Cancer Res 2 (2000), 438-443.
58. O. Minenkova et al., Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients, Int J Cancer 106 (2003), 534-544.
59. A. Mischo et al., Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients, Cancer Immun 3 (2003), 5.
60. R. B. Montgomery et al., Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase, Cancer Res 65 (2005), 650-656.
61. Y. Obata et al., Identification of Cancer Antigens in Breast Cancer by the SEREX Expression Cloning Method, Breast Cancer 6 (1999), 305-311.
62. D. M. Parkin et al., Global cancer statistics, 2002, CA Cancer J Clin 55 (2005), 74-108.
63. M. S. Pepe et al., Phases of biomarker development for early detectionofcancer, J Natl Cancer Inst 93 (2001), 1054-1061.
64. C. M. Perou et al., Distinctive gene expression patterns in human mammary epithelial cells and breast cancers, Proc Natl Acad Sci U S A 96 (1999), 9212-9217.
65. E. Petricoin et al., Clinical proteomics: revolutionizing disease detection and patient tailoring therapy, J Proteome Res 3 (2004), 209-217.
66. J. Qiu et al., Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera, J Clin Oncol 26 (2008), 5060-5066.
67. J. Qiu et al., Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens, J Proteome Res 3 (2004), 261-267.
68. A. K. Ramachandran N. J. Raphael, E. Hainsworth, S. Sibani, W. Montor, M. Pacek, J. Wong, M. Eljanne, M. J. Sanda, Y. Hu, T. Logvinenko, J. La Baer, Tracking humoral responses using self assembling protein microarrays, Proteomics-Clinical Applications 2 (2008), 1518-1527.
69. N. Ramachandran et al., Self-assembling protein microarrays, Science 305 (2004), 86-90.
70. N. Ramachandran et al., Next-generation high-density selfassembling functional protein arrays, Nat Methods 5 (2008), 535-538.
71. S. Regele et al., p53 autoantibodies can be indicative of the development of breast cancer relapse, Anticancer Res 23 (2003), 761-764.
72. W. H. Robinson et al., Autoantigen microarrays for multiplex characterization of autoantibody responses, Nat Med 8 (2002), 295-301.
73. M. Rodolfo et al., Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen, Cancer Res 63 (2003), 6948-6955.
74. J. G. Routsias et al., The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases, Clin Chim Acta 340 (2004), 1-25.
75. S. Rudchenko et al., A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen, BMC Cancer 8 (2008), 248.
76. S. Sangrajrang et al., Serum p53 antibodies in correlation to other biological parameters of breast cancer, Cancer Detect Prev 27 (2003), 182-186.
77. M. J. Scanlan et al., Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression, Cancer Immun 1 (2001), 4.
78. M. J. Scanlan et al., Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets, Cancer Res 62 (2002), 4041-4047.
79. A. L. Schechter et al., The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen, Nature 312 (1984), 513-516.
80. J. C. Schmollinger et al., Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction, Proc Natl Acad Sci U S A 100 (2003), 3398-3403.
81. H. Shimada et al., Titration of serum p53 antibodies in 1, 085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group, Cancer 97 (2003), 682-689.
82. M. Sioud et al., Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries, Eur J Immunol 31 (2001), 716-725.
83. T. Soussi, p53 Antibodies in the sera of patients with various types of cancer: a review, Cancer Res 60 (2000), 1777-1788.
84. P. N. Spanetal., Survivin is an independent prognostic marker for risk stratification of breast cancer patients, Clin Chem 50 (2004), 1986-1993.
85. E. W. St Clair et al., The fine specificity of anti-La antibodies induced in mice by immunization with recombinant human La autoantigen, J Immunol 144 (1990), 3868-3876.
86. E. Stockert et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens, J Exp Med 187 (1998), 1349-1354.
87. D. Stoll et al., Protein microarray technology, Front Biosci 7 (2002), c13-c32.
88. A. Takeda et al., Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability, Eur J Surg 167 (2001), 50-53.
89. M. S. Tamesa et al., Detection of autoantibodies against cyclophilin A and triosephosphate isomerase insera from breast cancer patients by proteomic analysis, Electrophoresis 30 (2009), 2168-2181.
90. R. M. Tamimi et al., Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women, J Natl Cancer Inst 99 (2007), 1178-1187.
91. R. M. Tamimi et al., Endogenous sex hormone levels and mammographic density among postmenopausal women, Cancer Epidemiol Biomarkers Prev 14 (2005), 2641-2647.
92. M. F. Templin et al., Protein microarrays: promising tools for proteomic research, Proteomics 3 (2003), 2155-2166.
93. J. E. Tomkiel et al., Autoimmunity to the M (r) 32, 000 subunit of replication protein A in breast cancer, Clin Cancer Res 8 (2002), 752-758.
94. G. E. Trivers et al., Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride, J Natl Cancer Inst 87 (1995), 1400-1407.
95. G. E. Trivers et al., Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer, Clin Cancer Res 2 (1996), 1767-1775.
96. C. J. Vennegoor et al., Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes, Cancer Lett 116 (1997), 93-101.
97. M. Volkmann et al., Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression, Oncology 63 (2002), 297-305.
98. S. von Mensdorff-Pouilly et al., Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours, Eur J Cancer 32 A (1996), 1325-1331.
99. C. C. Wang et al., Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer, Proc Natl Acad Sci U S A 105 (2008), 11661-11666.
100. X. Wang et al., Autoantibody signatures in prostate cancer, N Engl J Med 353 (2005), 1224-1235.
101. P. C. Willsher et al., The significance of p53 autoantibodies in the serum of patients with breast cancer, Anticancer Res 16 (1996), 927-930.
102. C. Wingren et al., Antibody-based microarrays, Methods Mol Biol 509 (2009), 57-84.
103. S. F. Winter et al., Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation, Cancer Res 52 (1992), 4168-4174.
104. J. Wong et al., Rapid Detection of Antibodies in Sera Using Multiplexed Self-Assembling Bead Arrays, Journal of Immunological Methods in press, 2009.
105. J. Wulfkuhle et al., New approaches to proteomic analysis of breast cancer, Proteomics 1 (2001), 1205-1215.
106. A. Yagihashi et al., Detection of autoantibodies to survivin and livin in sera from patients with breast cancer, Clin Chim Acta 362 (2005), 125-130. (Pubitemid 41597098)
107. S. C. Yan et al., Post-translational modifications of proteins: some problems left to solve, Trends Biochem Sci 14 (1989), 264-268.
108. J. K. Yi et al., Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis, Cancer Epidemiol Biomarkers Prev 18 (2009), 1357-1364.
109. L. Zhong et al., Autoantibodies as potential biomarkers for breast cancer, Breast Cancer Res 10 (2008), R40.
110. H. Zhu et al., Global analysis of protein activities using proteome chips, Science 293 (2001), 2101-2105.